查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401902

到 2030 年药物传输奈米药物的市场预测：按产品类型、模式、适应症、给药途径、最终用户和地区进行全球分析

Nanomedicine for Drug Delivery Market Forecasts to 2030 - Global Analysis By Product Type (Nanoparticles, Nanoshells, Nanodevices and Nanotubes), Modality (Treatments and Diagnostics), Indication, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球用于给药的奈米药物市场规模为 1,976 亿美元，预计在预测期内将以 13.5% 的复合年增长率增长，并在 2030 年达到 4,794 亿美元。

被称为「奈米医学」的医学领域利用奈米技术设备和专业知识来预防和治疗多种疾病。奈米颗粒可以设计用于靶向特定细胞或组织，透过将其直接递送至预定部位来减少副作用并提高药物疗效。奈米颗粒可以延长药物在体内的循环时间，使药物持续释放，减少用药给药。

根据美国癌症协会估计，2023 年美国女性中将诊断出 297,790 例新的侵袭性乳癌病例。奈米颗粒、奈米载体和其他奈米级药物传递平台具有独特的特性，可增强对药物稳定性、溶解度、生物利用度和释放动力学的控制。

慢性病增加

糖尿病、心臟病和癌症等慢性疾病变得越来越普遍。基于奈米医学的药物传输系统在提高治疗药物对抗这些疾病的功效方面显示出了有希望的结果。由于奈米粒子能够靶向特定细胞和组织并将药物直接输送到作用部位，因此慢性疾病的治疗变得更具吸引力。随着这些疾病的流行，对奈米药物在药物传输方面的需求不断增加。

安全问题

虽然奈米医学有很多好处，但也有人担心奈米粒子的安全性。奈米粒子的小尺寸和特殊的物理化学性质增加了意想不到的生物相互作用和毒性的可能性。奈米颗粒暴露和在体内累积的长期影响仍在研究中。奈米医学产品的市场接受度可能会受到安全问题的影响。

影像和诊断技术的进步

奈米医学对于电脑断层扫描 (CT)、正子断层扫描 (PET) 和磁振造影(MRI) 等诊断影像方式至关重要。透过设计携带成像剂的奈米颗粒，可以改善疾病检测和可视化。将诊断和治疗功能整合到奈米颗粒中可以实现将诊断和治疗相结合的治疗诊断应用。成像和诊断技术的开拓推动了奈米药物传输市场的扩张。

製造可扩展性

含有奈米药物的产品可能涉及复杂的製造过程，需要专门的设施和机械。在提高产量的同时保持最终产品的成本效益、一致性和品质时，需要克服许多障碍。製造奈米医学产品通常涉及复杂且耗时的奈米颗粒合成、精製和表征过程。生产具有精确尺寸、型态和表面特性的奈米粒子需要先进的技术和专业知识。因此，製造规模化是阻碍市场需求的主要因素。

COVID-19 的影响

COVID-19 大流行对药物输送奈米医学市场产生了重大影响。全球供应链中断导致基本成分短缺，并阻碍了奈米药物的生产。由于面对面互动有限，新应用的临床试验面临延误和中断，影响了研究进展。由于人们对标靶药物输送系统和远端医疗解决方案的关注，市场需求发生了波动，凸显了适应性强和精确的药物传递机制的重要性。这场大流行加速了远端医疗和远端患者监护的采用，影响了对支持这些新医疗方法的药物输送系统的需求。

奈米壳产业预计将在预测期内成为最大的产业

预计奈米壳领域将占据最大占有率。这些是核壳奈米粒子，其中薄金属壳（通常由银或金製成）包围介电核。由于它们的特殊结构，它们的光学特性、散射和吸收光的能力可以被精确控制。在药物传递方面，奈米壳被设计用于携带治疗剂并将其给药到体内的特定标靶位点。可以调整其尺寸和表面特性，以最大限度地提高与生物组织的相互作用。此外，由于金属外壳，它们可以对特定波长的光做出反应，这是标靶治疗和控制药物释放的重要特性。

预计肿瘤学领域在预测期内将经历最高的复合年增长率。

预计肿瘤疾病领域在预测期内将出现良好的成长。抗癌药物最大限度地减少对健康组织的损害，并且能够精确地靶向肿瘤。透过特异性辨识和结合癌细胞，这些奈米颗粒可以被设计来增强肿瘤部位的药物累积。此外，这些奈米载体的特殊性质可以调节药物的释放，从而产生持久和有针对性的治疗效果。由于尺寸小，奈米载体可以穿透肿瘤组织并到达常规药物难以到达的区域。

占有率最高的地区

在估计期间，北美占据了最大的市场占有率。对研发的大量投资和强大的卫生系统创造了有利于奈米技术创新发展的氛围。主要生物技术和製药公司的存在促进了团队合作，并促进了先进药物输送系统的开发。建立了创新和发现文化的学术机构和研究中心不断为该地区奈米医学的技术突破做出贡献。

复合年增长率最高的地区：

欧洲专注于研究和开发，已成为奈米医学药物传输的重要中心。这项创新由德国、英国、瑞士等国家引领，为科学研究和技术发展提供了丰富的环境。该地区专注于尖端方法，特别强调利用奈米技术的精准医疗和个人化治疗。欧洲是先进药物传输系统发展的驱动力，在全球奈米医学市场中发挥关键作用。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章依产品类型分類的全球药物传输奈米医学市场

  • 介绍
  • 奈米颗粒
    • 金属和金属氧化物奈米颗粒
    • 脂质体
    • 水凝胶奈米粒子
    • 聚合物和聚合物药物缀合物
    • 树状聚合物
    • 无机奈米粒子
  • 奈米壳
  • 奈米装置
  • 奈米管

第六章全球药物传输奈米医学市场：依方式分类

  • 介绍
  • 治疗
  • 诊断

第七章全球药物传输奈米医学市场：依适应症分类

  • 介绍
  • 感染疾病
  • 整形外科疾病
  • 肿瘤性疾病
  • 心血管疾病
  • 泌尿系统疾病
  • 神经系统疾病
  • 免疫疾病
  • 眼科疾病
  • 其他适应症

第八章全球药物传输奈米药物市场：依给药途径

  • 介绍
  • 胃肠外的
  • 口服
  • 吸入
  • 局部的

第九章全球药物传输奈米医学市场：依最终用户分类

  • 介绍
  • 专科诊所
  • 医院
  • 其他最终用户

第十章全球药物传输奈米医学市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Camurus AB
  • Celgene, Inc.
  • EyePoint Pharmaceuticals
  • EnColl Corporation
  • Cytimmune Sciences, Inc.
  • Ceramisphere Health Pty Limited
  • Cristal Therapeutics
  • Aquanova AG
  • BlueWillow Biologics
  • AbbVie Inc.
  • Amgen Foundation
  • Abbott
  • Cadila Pharmaceuticals
  • Novartis AG
  • Johnson & Johnson Services
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
Product Code: SMRC24422

According to Stratistics MRC, the Global Nanomedicine for Drug Delivery Market is accounted for $197.6 billion in 2023 and is expected to reach $479.4 billion by 2030 growing at a CAGR of 13.5% during the forecast period. The field of medicine known as "nanomedicine" employs instruments and expertise in nanotechnology to prevent and cure various illnesses. Nanoparticles can be engineered to target specific cells or tissues, reducing side effects and increasing the drug's effectiveness by delivering it directly to the intended site. Nanoparticles can extend a drug's circulation time in the body, allowing for a sustained release of medication and reducing the frequency of dosing.

According to American Cancer Society, it is estimated in 2023, about 297,790 new cases of invasive breast cancer will be diagnosed in women in U.S. Nanoparticles, nanocarriers, and other nanoscale drug delivery platforms offer unique properties that enhance drug stability, solubility, bioavailability, and control over release kinetics.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Chronic illnesses, including diabetes, heart disease, and cancer, are becoming more common. Nanomedicine-based drug delivery systems have shown promising results in improving the efficacy of therapeutic agents for these conditions. Treating chronic diseases has become more appealing for nanoparticles due to their capacity to target particular cells or tissues and deliver drugs directly to the site of action. The need for nanomedicine in drug delivery rises with the prevalence of these diseases.

Restraint:

Safety concerns

While nanomedicine offers numerous benefits, there are concerns regarding the safety of nanoparticles. Nanoparticles' small size and special physicochemical characteristics raise the possibility of unforeseen biological interactions and toxicity. The long-term effects of nanoparticle exposure and accumulation in the body are still being studied. The market's acceptance of nanomedicine products can be affected by safety concerns.

Opportunity:

Technological advancements in imaging and diagnostics

In diagnostic imaging methods like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI), nanomedicine is essential. It is possible to engineer nanoparticles to carry imaging agents, improving disease detection and visualization. The integration of diagnostic and therapeutic functions in nanoparticles allows for theranostic applications, where diagnosis and treatment can be combined. The expansion of the nanomedicine drug delivery market has been facilitated by developments in imaging and diagnostics.

Threat:

Manufacturing scalability

Products involving nanomedicines can have complicated manufacturing processes requiring specialized facilities and machinery. There are many obstacles to overcome when increasing production while preserving the cost-effectiveness, consistency, and quality of the final product. The production of nanomedicine products frequently entails the complex and time-consuming processes of synthesizing, purifying, and characterizing nanoparticles. Advanced technologies and expertise are needed to produce nanoparticles with precise size, shape, and surface characteristics. Therefore, manufacturing scalability is a significant factor hampering market demand.

COVID-19 Impact

The COVID-19 pandemic profoundly affected the nanomedicine for drug delivery market. Disruptions in the global supply chain led to shortages of essential components, hindering the production of nanomedicine. Clinical trials for new applications faced delays or halts due to restrictions on in-person interactions, impacting research progress. Market demand fluctuated as the focus turned toward targeted drug delivery systems and remote healthcare solutions, highlighting the importance of adaptable and precise drug delivery mechanisms. The pandemic accelerated the adoption of telemedicine and remote patient monitoring, influencing the demand for drug delivery systems that support these new healthcare approaches.

The nanoshells segment is expected to be the largest during the forecast period

The nanoshells segment is estimated to hold the largest share. These are core-shell nanoparticles, with a thin metallic shell (usually made of silver or gold) encircling a dielectric core. Because of their special structure, their optical characteristics, namely, their capacity to scatter and absorb light, can be precisely controlled. Nanoshells are designed to carry and administer therapeutic agents to particular target areas within the body when it comes to drug delivery. It is possible to adjust their size and surface characteristics to maximize interactions with biological tissues. Additionally, they can also react to particular light wavelengths due to their metallic shell, which is an essential characteristic for targeted therapy and controlled drug release.

The oncological diseases segment is expected to have the highest CAGR during the forecast period

The oncological diseases segment is anticipated to have lucrative growth during the forecast period. They minimize damage to healthy tissues and enable precise targeting of tumors. By specifically recognizing and binding to cancer cells, these nanoparticles can be engineered to enhance the drug's accumulation at the tumor site. Furthermore, these nanocarriers' special qualities allow for regulated drug release, resulting in long-lasting and targeted therapeutic effects. Because of their small size, they can penetrate tumor tissues and reach places that may be difficult for conventional medications to reach.

Region with largest share:

North America commanded the largest market share during the extrapolated period. Significant investments in research and development, in conjunction with a strong healthcare system, create an atmosphere that is favourable to innovative developments in nanotechnology. Leading biotech and pharmaceutical companies is present, which encourages teamwork and leads to the development of advanced drug delivery systems. Establishing a culture of innovation and discovery, academic institutions and research centers consistently contribute to technological breakthroughs in nanomedicine in this region.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period, owing to its strong focus on research and development, Europe is a prominent hub for nanomedicine in drug delivery. This innovation is driven by nations like Germany, the UK, and Switzerland, which provide a rich environment for scientific research and technological development. The region is focused on cutting-edge methods, with a particular emphasis on precision medicine and customized treatments utilizing nanotechnology. Europe as a driving force in the evolution of advanced drug delivery systems, making it a crucial player in the global nanomedicine market.

Key players in the market:

Some of the key players in the Nanomedicine for Drug Delivery Market include Camurus AB, Celgene, Inc., Eye Point Pharmaceuticals, EnColl Corporation, Cytimmune Sciences, Inc., Ceramisphere Health Pty Limited, Cristal Therapeutics, Aquanova AG, Blue Willow Biologics, AbbVie Inc., Amgen Foundation, Abbott, Cadila Pharmaceuticals , Novartis AG, Johnson & Johnson Services, Pfizer Inc., F. Hoffmann-La Roche Ltd and Eli Lilly and Company.

Key Developments:

In Dec 2022, Eli Lilly and Company and EVA Pharma announced a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low-to middle income.

In Aug 2022, Abbott and WeightWatchers announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight.

In June 2022, Pfizer announces Strategic Collaboration with Truveta to Accelerate Safety Insights in Real Time. Truveta will provide Pfizer with an unprecedented data platform for research. The data collected by Truveta are always flowing, providing the most up-to-date picture of U.S. health.

Product Types Covered:

  • Nanoparticles
  • Nanoshells
  • Nanodevices
  • Nanotubes

Modalities Covered:

  • Treatments
  • Diagnostics

Indications Covered:

  • Infectious Diseases
  • Orthopedic Disorders
  • Oncological Diseases
  • Cardiovascular Diseases
  • Urological Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Ophthalmological Diseases
  • Other Indications

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Inhalation
  • Topical

End Users Covered:

  • Specialty Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanomedicine for Drug Delivery Market, By Product Type

  • 5.1 Introduction
  • 5.2 Nanoparticles
    • 5.2.1 Metal and Metal Oxide Nanoparticles
    • 5.2.2 Liposomes
    • 5.2.3 Hydrogel Nanoparticles
    • 5.2.4 Polymers and Polymer Drug Conjugates
    • 5.2.5 Dendrimers
    • 5.2.6 Inorganic Nanoparticles
  • 5.3 Nanoshells
  • 5.4 Nanodevices
  • 5.5 Nanotubes

6 Global Nanomedicine for Drug Delivery Market, By Modality

  • 6.1 Introduction
  • 6.2 Treatments
  • 6.3 Diagnostics

7 Global Nanomedicine for Drug Delivery Market, By Indication

  • 7.1 Introduction
  • 7.2 Infectious Diseases
  • 7.3 Orthopedic Disorders
  • 7.4 Oncological Diseases
  • 7.5 Cardiovascular Diseases
  • 7.6 Urological Diseases
  • 7.7 Neurological Diseases
  • 7.8 Immunological Diseases
  • 7.9 Ophthalmological Diseases
  • 7.10 Other Indications

8 Global Nanomedicine for Drug Delivery Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Oral
  • 8.4 Inhalation
  • 8.5 Topical

9 Global Nanomedicine for Drug Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Specialty Clinics
  • 9.3 Hospitals
  • 9.4 Other End Users

10 Global Nanomedicine for Drug Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Camurus AB
  • 12.2 Celgene, Inc.
  • 12.3 EyePoint Pharmaceuticals
  • 12.4 EnColl Corporation
  • 12.5 Cytimmune Sciences, Inc.
  • 12.6 Ceramisphere Health Pty Limited
  • 12.7 Cristal Therapeutics
  • 12.8 Aquanova AG
  • 12.9 BlueWillow Biologics
  • 12.10 AbbVie Inc.
  • 12.11 Amgen Foundation
  • 12.12 Abbott
  • 12.13 Cadila Pharmaceuticals
  • 12.14 Novartis AG
  • 12.15 Johnson & Johnson Services
  • 12.16 Pfizer Inc.
  • 12.17 F. Hoffmann-La Roche Ltd
  • 12.18 Eli Lilly and Company

List of Tables

  • Table 1 Global Nanomedicine for Drug Delivery Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nanomedicine for Drug Delivery Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Nanomedicine for Drug Delivery Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 4 Global Nanomedicine for Drug Delivery Market Outlook, By Metal and Metal Oxide Nanoparticles (2021-2030) ($MN)
  • Table 5 Global Nanomedicine for Drug Delivery Market Outlook, By Liposomes (2021-2030) ($MN)
  • Table 6 Global Nanomedicine for Drug Delivery Market Outlook, By Hydrogel Nanoparticles (2021-2030) ($MN)
  • Table 7 Global Nanomedicine for Drug Delivery Market Outlook, By Polymers and Polymer Drug Conjugates (2021-2030) ($MN)
  • Table 8 Global Nanomedicine for Drug Delivery Market Outlook, By Dendrimers (2021-2030) ($MN)
  • Table 9 Global Nanomedicine for Drug Delivery Market Outlook, By Inorganic Nanoparticles (2021-2030) ($MN)
  • Table 10 Global Nanomedicine for Drug Delivery Market Outlook, By Nanoshells (2021-2030) ($MN)
  • Table 11 Global Nanomedicine for Drug Delivery Market Outlook, By Nanodevices (2021-2030) ($MN)
  • Table 12 Global Nanomedicine for Drug Delivery Market Outlook, By Nanotubes (2021-2030) ($MN)
  • Table 13 Global Nanomedicine for Drug Delivery Market Outlook, By Modality (2021-2030) ($MN)
  • Table 14 Global Nanomedicine for Drug Delivery Market Outlook, By Treatments (2021-2030) ($MN)
  • Table 15 Global Nanomedicine for Drug Delivery Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 16 Global Nanomedicine for Drug Delivery Market Outlook, By Indication (2021-2030) ($MN)
  • Table 17 Global Nanomedicine for Drug Delivery Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Nanomedicine for Drug Delivery Market Outlook, By Orthopedic Disorders (2021-2030) ($MN)
  • Table 19 Global Nanomedicine for Drug Delivery Market Outlook, By Oncological Diseases (2021-2030) ($MN)
  • Table 20 Global Nanomedicine for Drug Delivery Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 21 Global Nanomedicine for Drug Delivery Market Outlook, By Urological Diseases (2021-2030) ($MN)
  • Table 22 Global Nanomedicine for Drug Delivery Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 23 Global Nanomedicine for Drug Delivery Market Outlook, By Immunological Diseases (2021-2030) ($MN)
  • Table 24 Global Nanomedicine for Drug Delivery Market Outlook, By Ophthalmological Diseases (2021-2030) ($MN)
  • Table 25 Global Nanomedicine for Drug Delivery Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 26 Global Nanomedicine for Drug Delivery Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 27 Global Nanomedicine for Drug Delivery Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 28 Global Nanomedicine for Drug Delivery Market Outlook, By Oral (2021-2030) ($MN)
  • Table 29 Global Nanomedicine for Drug Delivery Market Outlook, By Inhalation (2021-2030) ($MN)
  • Table 30 Global Nanomedicine for Drug Delivery Market Outlook, By Topical (2021-2030) ($MN)
  • Table 31 Global Nanomedicine for Drug Delivery Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Nanomedicine for Drug Delivery Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 33 Global Nanomedicine for Drug Delivery Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 34 Global Nanomedicine for Drug Delivery Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.